Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses

6 Months Ended

Jun. 30, 2020

Note 7 - Accounts Payable and Accrued Expenses

At June 30, 2020 and December 31, 2019, accounts payable and accrued expenses consisted of the following ($ in thousands):


	June 30,		December 31,
	2020		2019
Accounts payable	$	2,321	$	3,079
Accrued compensation		223		414
Research and development		3,757		3,496
Other		373		268
Accounts payable and accrued expenses - related party		1,037		862
Total accounts payable and accrued expenses	$	7,711	$	8,119